Stocktoria

Climb Bio, Inc. CLYM

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-08-10

Climb Bio, Inc. statistics & valuation

Market cap$749.0M
P / B4.7×
Return on equity-37.3%
Return on capital-42.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
202020212022202320242025
Return on equity (%)
-28.40% -35.20% -32.60% -34.90% -37.30% 202020212022202320242025
Shares outstanding
3.4M 26.6M 26.6M 27.7M 67.3M 67.8M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-83.90% -27.40% -33.50% -31.80% -34.00% -35.70% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$4.24 -$1.72 -$1.30 -$1.53 -$0.88 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-35.7%-34.0%-31.8%-33.5%-27.4%-83.9%
Return on equity-37.3%-34.9%-32.6%-35.2%-28.4%82.7%
Current ratio15.1631.4138.9222.0424.587.18

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.